Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and lowers the price target from $19 to $18.
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and lowers the price target from $19 to $18.